Peter Anthony Campochiaro, M.D.

Headshot of Peter Anthony Campochiaro
  • Director, Retinal Cell and Molecular Laboratory
  • Professor of Ophthalmology


Diabetic Macular Edema, Diabetic Retinopathy, Macular Degeneration, Macular Disorders, Macular Holes, Macular Puckers, Ophthalmology, Proliferative Vitreoretinopathy, Retinal Detachment, Retinal Disease, Retinal Specialist, Retinal Surgery, Retinal Vascular Disease, Retinal Vessel Occlusion, Surgical and Medical Diseases of the Retina, Surgical Diseases of the Retina, Vitreoretinal Diseases and Surgery Service more

Research Interests

Mechanisms involved in ocular neovascularization; Development of new treatments for ocular neovascularization; Mechanisms involved in retinal degenerations; Development of new treatments for retinal degenerations; Ocular Gene Therapy; Clinical trials of ocular neovascularization and macular edema more

Request an Appointment

Insurance Information

Main Phone

Outside of Maryland & Washington D.C.

Request Appointment

International Patients

Request Appointment


The Johns Hopkins Hospital

Appointment Phone: 410-955-3518
600 N. Wolfe Street
Wilmer Eye Institute
Baltimore, MD 21287 map
Phone: 410-955-3518 | Fax: 410-614-7083


Peter A. Campochiaro, M.D. is the George S. and Dolores Doré Eccles Professor of Ophthalmology and Neuroscience at the Wilmer Eye Institute, Johns Hopkins University School of Medicine. He is a clinician-scientist who directs a research laboratory and conducts clinical trials. His laboratory research is directed at understanding the pathogenesis of ocular neovascularization and excessive retinal vascular permeability, and the mechanism of cone cell death in inherited retinal degenerations. He helped to determine the importance of vascular endothelial growth factor (VEGF), hypoxia-inducible factor-1, and Tie2 in retinal and choroidal vascular diseases.

The clinical trial group under Dr. Campochairo provided the first demonstration of the benefits of suppression of VEGF in diabetic macular edema and retinal vein occlusion. He has developed strategies for sustained suppression of VEGF that are currently being tested in clinical trials. 

Dr. Campochiaro trained at the University of Notre Dame, Johns Hopkins School of Medicine, and the University of Virginia. He did a vitreoretinal fellowship and research fellowships at Johns Hopkins and joined the faculty of the University of Virginia in 1984. He became professor of Ophthalmology and Neuroscience at the Wilmer Eye Institute, Johns Hopkins in 1991. more


  • Director, Retinal Cell and Molecular Laboratory
  • George S. and Dolores Dore Eccles Professor of Ophthalmology and Neuroscience
  • Professor of Ophthalmology
  • Professor of Neuroscience

Departments / Divisions

Centers & Institutes



  • MD; Johns Hopkins University School of Medicine (1978)


  • Ophthalmology; University of Virginia School of Medicine (1982)

Board Certifications

  • American Board of Ophthalmology (Ophthalmology) (1983)

Research & Publications


Lab Website: Retinal Cell and Molecular Laboratory

Clinical Trial Keywords

Diabetic macular edema; Ranibizumab; Central retinal vein occlusion; Branch retinal vein occlusion; Choroidal neovascularization; Gene therapy

Activities & Honors


  • Retina Hall of Fame, 2017
  • Arnall Patz Medal, Macula Society, 2012

Videos & Media

Recent News Articles and Media Coverage

NAC Attacks Retinitis Pigmentosa, Wilmer Insider (Apr. 2021)

What's the Difference Between Dry and Wet AMD?, US News and World Report (Sept. 2019)

Johns Hopkins Researchers Advance Search For Safer, Easier Way to Deliver Vision-Saving Gene Therapy to The Retina, Hopkins Newsroom (Sept. 2019)

Patient Ratings & Comments

The Patient Rating score is an average of all responses to physician related questions on the national CG-CAHPS Medical Practice patient experience survey through Press Ganey. Responses are measured on a scale of 1 to 5, with 5 being the best score. Comments are also gathered from our CG-CAHPS Medical Practice Survey through Press Ganey and displayed in their entirety. Patients are de-identified for confidentiality and patient privacy.

Is this you? Edit Profile
back to top button